The San Diego biotech has filed a lawsuit against the Japanese drugmaker and its US subsidiary, NS Pharma, claiming that the ...

Daiichi Sankyo has reported its delayed financial results, saying that high spending on third-party manufacturing and a lower-than-expected take-up of its antibody-drug conjugates for cancer led to a ...

Longevity investment went from $3.8bn in 2023 to $8.5bn in 2024 (albeit in the context of a broader biotech market recovery).

Specifically, the FDA is delaying its verdict on once-weekly Leqembi Iqlik (lecanemab) as a starting dose for patients ...

Swiss biotech Windward Bio is planning to take on some heavyweight rivals with its TSLP-acting drug for inflammatory respiratory and dermatological diseases – a mission that will be helped by adding ...

The company behind a search agent to assist clinical decision-making – OpenEvidence – has raised an impressive $210 million in a second-round financing that will support the launch of a tool that can ...

Generate Biomedicines has filed for an IPO on the Nasdaq, seeking to raise upwards of $100 million for its AI-powered drug discovery operations. Incubated by Flagship Pioneering, Generate applies AI ...

Top priorities at the FDA in the coming years will include shorter review timelines for drug development, embracing the use of artificial intelligence and big data, and speeding up approvals for ...

CSL has FDA approval for its new drug to prevent hereditary angioedema (HAE) attacks, Andembry, offering a new, first-in-class option for patients with the rare genetic disorder. Factor XIIa inhibitor ...

Danish GLP-1 giant Novo Nordisk announced a restructuring effort today that will cut 9,000 jobs, a little over 11% of its global workforce. The cut comes a little over a month after the start of new ...

Jazz Pharmaceuticals has become the first drugmaker to get FDA approval for a treatment for diffuse midline glioma with H3 K27M mutations, a rare brain cancer mainly affecting young people. The ...

A year ago, Iovance was celebrating becoming the first company to win FDA clearance for a cell therapy used to treat a solid tumour. Now, it is cutting staff in the face of sales growth that has not ...